BrantlyM.L., SpencerL.T., HumphriesM.et al.2006. Phase I trial of intramuscular injection of a recombinant adeno-associated serotype 2 AAV vector in AAT-deficient adults. Hum. Gene Ther., 17:1–10.
2.
BrantlyM.L., ChulayJ.D., WangL.et al.2009. Sustained transgene expression despite T lymphocyte responses in a clinical trial of rAAV1-AAT gene therapy. Proc. Natl. Acad. Sci. U.S.A., 106:16363–16368.
3.
ClementN., KnopD.R., ByrneB.J.2009. Large-scale adeno-associated viral vector production using a herpesvirus-based system enables manufacturing for clinical studies. Hum. Gene Ther., 20:796–806.
4.
FlotteT.R., CarterB.J, ConradC.Ket al.1996. A phase I study of an adeno-associated virus-CFTR gene vector in adult CF patients with mild lung disease. Hum. Gene Ther., 7:1145–1159.
5.
FlotteT.R., ZeitlinP.L., ReynoldsT.C.et al.2003. Phase I trial of intranasal and endobronchial administration of a recombinant adeno-associated virus serotype (rAAV2)-CFTR vector in adult cystic fibrosis patients: A two-part clinical study. Hum. Gene Ther., 14:1079–1088.
NathwaniA., TuddenhamE., RosalesC.et al.2010. Early clinical trial results following administration of a low dose of a novel self-complementary adeno-associated viral vector encoding human factor IX in two subjects with severe hemophilia B. Blood. ASH Annual Meeting Abstracts, 116Abstract 248.
8.
WrightJ.F.2011. New adeno-associated virus strategies to support momentum in the clinic. Hum. Gene Ther., 22:519–521.
